290 related articles for article (PubMed ID: 24420815)
1. Molecular therapy of colorectal cancer: progress and future directions.
Weng W; Feng J; Qin H; Ma Y
Int J Cancer; 2015 Feb; 136(3):493-502. PubMed ID: 24420815
[TBL] [Abstract][Full Text] [Related]
2. Potential targets for prevention of colorectal cancer: a focus on PI3K/Akt/mTOR and Wnt pathways.
Pandurangan AK
Asian Pac J Cancer Prev; 2013; 14(4):2201-5. PubMed ID: 23725112
[TBL] [Abstract][Full Text] [Related]
3. Targeting PI3K signaling as a therapeutic approach for colorectal cancer.
Zhang J; Roberts TM; Shivdasani RA
Gastroenterology; 2011 Jul; 141(1):50-61. PubMed ID: 21723986
[TBL] [Abstract][Full Text] [Related]
4. Novel targets for anticancer treatment development in colorectal cancer.
Macarulla T; Ramos FJ; Capdevila J; Saura C; Tabernero J
Clin Colorectal Cancer; 2006 Nov; 6(4):265-72. PubMed ID: 17241511
[TBL] [Abstract][Full Text] [Related]
5. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
Gadgeel SM; Wozniak A
Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
[TBL] [Abstract][Full Text] [Related]
6. The promise of mTOR inhibitors in the treatment of colorectal cancer.
Kim DD; Eng C
Expert Opin Investig Drugs; 2012 Dec; 21(12):1775-88. PubMed ID: 22978346
[TBL] [Abstract][Full Text] [Related]
7. Targeting NF-kappaB for colorectal cancer.
Sakamoto K; Maeda S
Expert Opin Ther Targets; 2010 Jun; 14(6):593-601. PubMed ID: 20367537
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor: pathway, therapies, and pipeline.
Goffin JR; Zbuk K
Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
[TBL] [Abstract][Full Text] [Related]
9. On target? Strategies and progress in the development of therapies for colorectal cancer targeted against WNT signalling.
McDonald SL; Silver AR
Colorectal Dis; 2011 Apr; 13(4):360-9. PubMed ID: 20015264
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers and patient selection for PI3K/Akt/mTOR targeted therapies: current status and future directions.
Bartlett JM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S86-95. PubMed ID: 21115427
[TBL] [Abstract][Full Text] [Related]
11. Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck.
Simpson DR; Mell LK; Cohen EE
Oral Oncol; 2015 Apr; 51(4):291-8. PubMed ID: 25532816
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic evaluation of aflibercept for the treatment of colorectal cancer.
Sanz-Garcia E; SaurĂ T; Tabernero J; Macarulla T
Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):995-1004. PubMed ID: 25988772
[TBL] [Abstract][Full Text] [Related]
13. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
Mabuchi S; Kuroda H; Takahashi R; Sasano T
Gynecol Oncol; 2015 Apr; 137(1):173-9. PubMed ID: 25677064
[TBL] [Abstract][Full Text] [Related]
14. Molecular predictors of response to chemotherapy in colorectal cancer.
Dienstmann R; Vilar E; Tabernero J
Cancer J; 2011; 17(2):114-26. PubMed ID: 21427555
[TBL] [Abstract][Full Text] [Related]
15. New biologic agents for the treatment of gynecologic cancers.
Horowitz N; Matulonis UA
Hematol Oncol Clin North Am; 2012 Feb; 26(1):133-56. PubMed ID: 22244666
[TBL] [Abstract][Full Text] [Related]
16. Role of first-line anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy in advanced colorectal cancer: a meta-analysis of randomized clinical trials.
Khattak MA; Martin H; Davidson A; Phillips M
Clin Colorectal Cancer; 2015 Jun; 14(2):81-90. PubMed ID: 25666296
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.
De Mattia E; Cecchin E; Toffoli G
Drug Resist Updat; 2015 May; 20():39-70. PubMed ID: 26027741
[TBL] [Abstract][Full Text] [Related]
18. New approaches and targets in advanced colorectal cancer.
Macarulla T; Capdevila J; Perez-Garcia J; Ramos FJ; Elez ME; Markman B; Ruiz-Echarri M; Tabernero J
Eur J Cancer; 2009 Sep; 45 Suppl 1():79-88. PubMed ID: 19775607
[No Abstract] [Full Text] [Related]
19. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
20. The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer.
Van Cutsem E; Geboes K
Best Pract Res Clin Gastroenterol; 2007; 21(6):1089-108. PubMed ID: 18070705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]